<DOC>
	<DOC>NCT01627106</DOC>
	<brief_summary>This study will compare vernakalant therapy to amiodarone therapy in the acute management of recent onset atrial fibrillation.</brief_summary>
	<brief_title>A Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation (AF) (MK-6621-055)</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Amiodarone</mesh_term>
	<criteria>Symptomatic AF (duration of current episode is â‰¤7 days), which is hemodynamically stable, and participant has no other condition at the time of screening that may result in acute hospitalization If female and of reproductive potential, the patient agrees to remain abstinent or use 2 acceptable methods of birth control from time of screening until 30day followup. Weigh at least 45 kg Receiving adequate anticoagulant therapy Hypersensitivity to the vernakalant or amiodarone or to citric acid, sodium chloride, sodium hydroxide, or iodine Severe aortic stenosis Systolic blood pressure &lt;100 mmHg New York Heart Association (NYHA) Class III or IV heart failure Severe bradycardia, sinus node dysfunction, or second and third degree heart block in the absence of a pacemaker Use of IV rhythm control antiarrhythmics (Class I and III) within 4 hours of study drug administration Acute coronary syndrome (including myocardial infarction) within previous 30 days History of thyroid dysfunction Severe acute respiratory failure or cardiovascular collapse Participating in another drug study or has received an investigational drug within 30 days prior to enrollment Pregnant or breastfeeding, or expecting to conceive from time of screening until 30day followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>